Chemistry:PF-03654746
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H24F2N2O |
| Molar mass | 322.392 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
PF-03654746 is a potent and selective histamine H3 receptor antagonist developed by Pfizer and currently undergoing clinical trials for the treatment of ADHD, Tourette syndrome[1] as well as potential anti-allergy applications.[2][3][4][5]
References
- ↑ Clinical trial number NCT01475383 for "Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome" at ClinicalTrials.gov
- ↑ "The Effects of an H3 Receptor Antagonist in a Nasal Allergen Challenge Model". Journal of Allergy and Clinical Immunology 125 (2): AB191. 2010. doi:10.1016/j.jaci.2009.12.750.
- ↑ "H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers". Alzheimer's & Dementia 5 (4): P254. doi:10.1016/j.jalz.2009.04.272.
- ↑ "The histamine H3 receptor as a therapeutic drug target for CNS disorders". Drug Discovery Today 14 (9–10): 509–15. May 2009. doi:10.1016/j.drudis.2009.02.011. PMID 19429511.
- ↑ "Histamine H3 receptor ligands with a 3-cyclobutoxy motif: a novel and versatile constraint of the classical 3-propoxy linker". MedChemComm 1: 39. 2010. doi:10.1039/c0md00056f.
 |  |
